Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lyra Therapeutics, Inc.LYRA · Entity 46837 | Director | May 14, 2026 | May 15, 2026 |
| OCULAR THERAPEUTIX, INCOCUL · Entity 273 | CFO and Treasurer | January 31, 2017 | February 10, 2017 |
| Q32 Bio Inc.FIXX · Entity 5594 | See remarks | February 23, 2023 | February 27, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lyra Therapeutics, Inc.
Report date May 14, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Disposition to issuer · Disposed 640 · Balance 0 |
OCULAR THERAPEUTIX, INC
Report date January 31, 2017 · Filed February 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.56 · Expires 2027-01-30 | Direct | 90,000 |
Reported balance
After 2017-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-31 · Grant · Acquired 90,000 · Balance 90,000 F1: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.
Q32 Bio Inc.
Report date February 23, 2023 · Filed February 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2033-02-23 | Direct | 213,000 |
Reported balance
After 2023-02-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-23 · Grant · Acquired 213,000 · Balance 213,000 F1: The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2023. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 36,000 |
Reported balance
After 2023-02-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-23 · Grant · Acquired 36,000 · Balance 36,000 F2: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date. F3: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2023 so that such RSUs will become fully vested on January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2023.
F2: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date.
F3: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2023 so that such RSUs will become fully vested on January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 15, 2026 23:48 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | Disposition to issuerCommon Stock | 640 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-227500 · ownership.xml · nonDerivative · entry 1 Smith W Bradford · CIK 0001317678 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:30 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantRestricted Stock Units · Derivative | 32,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073606 · ownership.xml · derivative · entry 1 Smith W Bradford · CIK 0001317678 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 20:10 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 30,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0000950170-24-073647 · ownership.xml · derivative · entry 1 Smith W Bradford · CIK 0001317678 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 01:52 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0000950170-23-031872 · ownership.xml · derivative · entry 1 Smith W Bradford · CIK 0001317678 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-29 F1 · derivative.exercise_date: This option vests and becomes exercisable on June 30, 2024, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantRestricted Stock Units · Derivative | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-006207 · doc4.xml · derivative · entry 2 Smith W Bradford · CIK 0001317678 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date. F3 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2023 so that such RSUs will become fully vested on January 1, 2026. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee Stock Option (Right to Buy) · Derivative | 213,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0000899243-23-006207 · doc4.xml · derivative · entry 1 Smith W Bradford · CIK 0001317678 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,000 Underlying: Common Stock · 213,000 shares Expires 2033-02-23 F1 · derivative.exercise_date: The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2023. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 3,729 | $1.39 | $5,187.78 |
DisclosureSEC source: 0000899243-23-001576 · doc4.xml · nonDerivative · entry 1 Smith W Bradford · CIK 0001317678 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,219 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of restricted stock units. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $1.39 to $1.41. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 2. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 21:34 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionRestricted Stock Units · Derivative | 6,930 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-000626 · doc4.xml · derivative · entry 4 Smith W Bradford · CIK 0001317678 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,070 Underlying: Common Stock · 6,930 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. The RSUs do not have an expiration date. F3 · derivative.expiration_date: The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. The RSUs do not have an expiration date. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 21:34 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionRestricted Stock Units · Derivative | 6,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-000626 · doc4.xml · derivative · entry 3 Smith W Bradford · CIK 0001317678 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date. F2 · derivative.expiration_date: The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 21:34 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 6,930 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-000626 · doc4.xml · nonDerivative · entry 2 Smith W Bradford · CIK 0001317678 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 21:34 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 6,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-000626 · doc4.xml · nonDerivative · entry 1 Smith W Bradford · CIK 0001317678 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:06 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 7,250 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0000899243-22-023339 · doc4.xml · derivative · entry 1 Smith W Bradford · CIK 0001317678 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 Underlying: Common Stock · 7,250 shares Expires 2032-06-15 F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) June 16, 2023 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 21:06 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantRestricted Stock Units · Derivative | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-008064 · doc4.xml · derivative · entry 2 Smith W Bradford · CIK 0001317678 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date. F3 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 21:06 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee Stock Option (Right to Buy) · Derivative | 126,000 | $0.00 Strike: $2.71 | $0.00 |
DisclosureSEC source: 0000899243-22-008064 · doc4.xml · derivative · entry 1 Smith W Bradford · CIK 0001317678 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 2032-02-24 F1 · derivative.exercise_date: The option vests in 48 substantially equal monthly installments on the first day of each calendar month following January 1, 2022. Read SEC document |
| January 05, 2022 Filed Jan 12, 2022 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 2,182 | $3.78 | $8,248.40 |
DisclosureSEC source: 0000899243-22-001749 · doc4.xml · nonDerivative · entry 2 Smith W Bradford · CIK 0001317678 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,418 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $3.78 to $3.80. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3. Read SEC document |
| January 01, 2022 Filed Jan 12, 2022 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionRestricted Stock Units · Derivative | 6,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001749 · doc4.xml · derivative · entry 3 Smith W Bradford · CIK 0001317678 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,400 Underlying: Common Stock · 6,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The RSUs have vested and settled or will vest and settle, as applicable, as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date. F4 · derivative.expiration_date: The RSUs have vested and settled or will vest and settle, as applicable, as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date. Read SEC document |
| January 01, 2022 Filed Jan 12, 2022 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 6,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001749 · doc4.xml · nonDerivative · entry 1 Smith W Bradford · CIK 0001317678 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| May 26, 2021 Filed May 28, 2021 22:23 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 7,250 | $0.00 Strike: $7.24 | $0.00 |
DisclosureSEC source: 0000899243-21-021185 · doc4.xml · derivative · entry 1 Smith W Bradford · CIK 0001317678 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 Underlying: Common Stock · 7,250 shares Expires 2031-05-25 F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) May 26, 2022 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 21:22 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 13,500 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0000899243-21-005458 · doc4.xml · derivative · entry 5 Smith W Bradford · CIK 0001317678 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,904 Underlying: Common Stock · 13,500 shares Expires 2027-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was April 3, 2017. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 21:22 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 13,500 | $14.25 | $192,424.95 |
DisclosureSEC source: 0000899243-21-005458 · doc4.xml · nonDerivative · entry 2 Smith W Bradford · CIK 0001317678 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $14.00 to $14.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 21:22 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 13,500 | $0.64 | $8,640.00 |
DisclosureSEC source: 0000899243-21-005458 · doc4.xml · nonDerivative · entry 1 Smith W Bradford · CIK 0001317678 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 21:22 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-005458 · doc4.xml · derivative · entry 4 Smith W Bradford · CIK 0001317678 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. F5 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 21:22 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee Stock Option (Right to Buy) · Derivative | 122,000 | $0.00 Strike: $13.78 | $0.00 |
DisclosureSEC source: 0000899243-21-005458 · doc4.xml · derivative · entry 3 Smith W Bradford · CIK 0001317678 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,000 Underlying: Common Stock · 122,000 shares Expires 2031-02-05 F3 · derivative.exercise_date: The option vests in 48 equal monthly installments on the first day of each calendar month following January 1, 2021. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:06 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionEmployee Stock Option · Derivative | 12,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0000899243-20-003248 · doc4.xml · derivative · entry 3 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,404 Underlying: Common Stock · 12,000 shares Expires 2027-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was April 3, 2017. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:06 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 12,000 | $16.16 | $193,866.00 |
DisclosureSEC source: 0000899243-20-003248 · doc4.xml · nonDerivative · entry 2 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.0300 to $16.3400. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:06 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 12,000 | $0.63 | $7,579.20 |
DisclosureSEC source: 0000899243-20-003248 · doc4.xml · nonDerivative · entry 1 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:32 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionEmployee Stock Option · Derivative | 6,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0000899243-20-000313 · doc4.xml · derivative · entry 3 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,404 Underlying: Common Stock · 6,000 shares Expires 2027-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was April 3, 2017. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:32 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 6,000 | $20.50 | $122,984.40 |
DisclosureSEC source: 0000899243-20-000313 · doc4.xml · nonDerivative · entry 2 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $20.4200 to $20.6500. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:32 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 6,000 | $0.63 | $3,789.60 |
DisclosureSEC source: 0000899243-20-000313 · doc4.xml · nonDerivative · entry 1 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee Stock Option (Right to Buy) · Derivative | 111,000 | $0.00 Strike: $19.92 | $0.00 |
DisclosureSEC source: 0000899243-19-029153 · doc4.xml · derivative · entry 1 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,000 Underlying: Common Stock · 111,000 shares Expires 2029-12-11 F1 · derivative.exercise_date: The option vests in 48 equal monthly installments on the first day of each calendar month following January 1, 2020. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:07 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionEmployee Stock Option · Derivative | 6,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0000899243-19-028395 · doc4.xml · derivative · entry 6 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,404 Underlying: Common Stock · 6,000 shares Expires 2027-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was April 3, 2017. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:07 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 6,000 | $16.21 | $97,266.00 |
DisclosureSEC source: 0000899243-19-028395 · doc4.xml · nonDerivative · entry 4 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.03 to $16.35. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:07 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 6,000 | $0.64 | $3,840.00 |
DisclosureSEC source: 0000899243-19-028395 · doc4.xml · nonDerivative · entry 3 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 21:07 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionEmployee Stock Option · Derivative | 6,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0000899243-19-028395 · doc4.xml · derivative · entry 5 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,404 Underlying: Common Stock · 6,000 shares Expires 2027-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was April 3, 2017. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 21:07 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 6,000 | $16.00 | $96,000.00 |
DisclosureSEC source: 0000899243-19-028395 · doc4.xml · nonDerivative · entry 2 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 21:07 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 6,000 | $0.64 | $3,840.00 |
DisclosureSEC source: 0000899243-19-028395 · doc4.xml · nonDerivative · entry 1 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 20:08 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionEmployee Stock Option · Derivative | 6,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0000899243-19-024658 · doc4.xml · derivative · entry 4 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,404 Underlying: Common Stock · 6,000 shares Expires 2027-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was April 3, 2017. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 20:08 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 100 | $18.23 | $1,823.00 |
DisclosureSEC source: 0000899243-19-024658 · doc4.xml · nonDerivative · entry 3 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 20:08 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 5,900 | $17.38 | $102,543.77 |
DisclosureSEC source: 0000899243-19-024658 · doc4.xml · nonDerivative · entry 2 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.10 to $17.85. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 20:08 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 6,000 | $0.64 | $3,840.00 |
DisclosureSEC source: 0000899243-19-024658 · doc4.xml · nonDerivative · entry 1 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 20:42 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionEmployee Stock Option · Derivative | 6,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0000899243-19-022841 · doc4.xml · derivative · entry 3 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,404 Underlying: Common Stock · 6,000 shares Expires 2027-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was April 3, 2017. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 20:42 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 6,000 | $18.74 | $112,419.00 |
DisclosureSEC source: 0000899243-19-022841 · doc4.xml · nonDerivative · entry 2 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.36 to $19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 20:42 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 6,000 | $0.64 | $3,840.00 |
DisclosureSEC source: 0000899243-19-022841 · doc4.xml · nonDerivative · entry 1 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 20:16 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionEmployee Stock Option · Derivative | 6,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0000899243-19-020992 · doc4.xml · derivative · entry 3 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,404 Underlying: Common Stock · 6,000 shares Expires 2027-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was April 3, 2017. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 20:16 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 6,000 | $17.37 | $104,190.60 |
DisclosureSEC source: 0000899243-19-020992 · doc4.xml · nonDerivative · entry 2 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.73 to $17.68. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 20:16 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 6,000 | $0.64 | $3,840.00 |
DisclosureSEC source: 0000899243-19-020992 · doc4.xml · nonDerivative · entry 1 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:30 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionEmployee Stock Option · Derivative | 6,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0000899243-19-019175 · doc4.xml · derivative · entry 3 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,404 Underlying: Common Stock · 6,000 shares Expires 2027-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was April 3, 2017. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:30 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 6,000 | $19.00 | $113,971.20 |
DisclosureSEC source: 0000899243-19-019175 · doc4.xml · nonDerivative · entry 2 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.53 to $19.48. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:30 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 6,000 | $0.64 | $3,840.00 |
DisclosureSEC source: 0000899243-19-019175 · doc4.xml · nonDerivative · entry 1 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 22:16 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionEmployee Stock Option · Derivative | 6,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0000899243-19-015653 · doc4.xml · derivative · entry 3 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,404 Underlying: Common Stock · 6,000 shares Expires 2027-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was April 3, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.